- Home
- JTAI vs TOVX Comparison
JTAI vs TOVX Comparison
Compare JTAI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- TOVX
- Stock Information
- Founded
- JTAI 2018
- TOVX 2001
- Country
- JTAI United States
- TOVX United States
- Employees
- JTAI N/A
- TOVX N/A
- Industry
- JTAI Blank Checks
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- TOVX Health Care
- Exchange
- JTAI Nasdaq
- TOVX Nasdaq
- Market Cap
- JTAI 3.4M
- TOVX 3.5M
- IPO Year
- JTAI N/A
- TOVX 2006
- Fundamental
- Price
- JTAI $3.95
- TOVX $1.21
- Analyst Decision
- JTAI
- TOVX Strong Buy
- Analyst Count
- JTAI 0
- TOVX 1
- Target Price
- JTAI N/A
- TOVX $6.00
- AVG Volume (30 Days)
- JTAI 1.2M
- TOVX 102.1K
- Earning Date
- JTAI 11-14-2024
- TOVX 11-12-2024
- Dividend Yield
- JTAI N/A
- TOVX N/A
- EPS Growth
- JTAI N/A
- TOVX N/A
- EPS
- JTAI N/A
- TOVX N/A
- Revenue
- JTAI $15,028,926.00
- TOVX N/A
- Revenue This Year
- JTAI $21.49
- TOVX N/A
- Revenue Next Year
- JTAI $10.05
- TOVX N/A
- P/E Ratio
- JTAI N/A
- TOVX N/A
- Revenue Growth
- JTAI 46.66
- TOVX N/A
- 52 Week Low
- JTAI $3.51
- TOVX $1.14
- 52 Week High
- JTAI $731.25
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- JTAI 31.95
- TOVX 37.37
- Support Level
- JTAI $3.64
- TOVX $1.15
- Resistance Level
- JTAI $5.10
- TOVX $1.34
- Average True Range (ATR)
- JTAI 0.65
- TOVX 0.07
- MACD
- JTAI 0.51
- TOVX 0.01
- Stochastic Oscillator
- JTAI 18.86
- TOVX 7.41
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.